Drug Profile
AZD 5055
Alternative Names: AZD-5055; RXC-006Latest Information Update: 22 Dec 2023
Price :
$50
*
At a glance
- Originator Redx Pharma
- Developer AstraZeneca
- Class Antifibrotics; Small molecules
- Mechanism of Action PORCN protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 04 Dec 2023 AstraZeneca completes a phase I trial for Idiopathic pulmonary fibrosis (In volunteers) in USA (PO) (NCT05955183)
- 27 Jul 2023 AstraZeneca initiates enrolment in a phase I trial for Idiopathic pulmonary fibrosis (In volunteers) in USA (PO) (NCT05955183)
- 21 Jul 2023 AstraZeneca plans a phase I trial in volunteers in USA (PO)(NCT05955183)